デフォルト表紙
市場調査レポート
商品コード
1466354

吸入・点鼻スプレーのジェネリック医薬品市場:適応症別、年齢層別、薬剤クラス別、ルート別、流通チャネル別-2024~2030年の世界予測

Inhalation & Nasal Sprays Generic Drugs Market by Indication (Allergic Rhinitis, Asthma, COPD), Age Group (Adults, Children 2 to 5, Children 6 to 12), Class, Route, Distribution Channel - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
吸入・点鼻スプレーのジェネリック医薬品市場:適応症別、年齢層別、薬剤クラス別、ルート別、流通チャネル別-2024~2030年の世界予測
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

吸入・点鼻スプレーのジェネリック医薬品市場規模は、2023年に80億9,000万米ドルと推定され、2024年には87億8,000万米ドルに達し、CAGR 8.61%で2030年には144億3,000万米ドルに達すると予測されます。

吸入・点鼻スプレーのジェネリック医薬品は、ブランド医薬品と生物学的に同等な特許切れ医薬品です。ジェネリック医薬品は同じ有効成分を含み、同じ投与経路で投与され、先発医薬品と同じ治療効果をもたらすことを目的としています。これらのジェネリック医薬品は、先発医薬品の独占特許期間後に製造されることが多く、一般的に低価格で提供されるため、呼吸器疾患、アレルギー、その他の鼻や肺の問題の治療を必要とする患者が広く利用できるようになります。吸入・点鼻スプレー用ジェネリック医薬品市場は、主に呼吸器疾患の有病率の増加、ジェネリック医薬品の費用対効果、先発医薬品の特許切れによって牽引されています。また、新興市場におけるアクセシビリティの向上や、軽度の疾患に対するセルフメディケーションの受け入れ拡大も市場成長に寄与しています。しかし、大規模な文書化や臨床試験を必要とする厳しい規制の枠組みは、製品の商業化を遅らせる可能性があります。先発医薬品との競合、限られた医療予算、価格圧力も、吸入・点鼻スプレーのジェネリック事業にとって大きなハードルとなっています。こうした課題にもかかわらず、より優れた送達システムと患者のコンプライアンス面を備えた生物学的に同等なジェネリック医薬品の研究開発は、潜在的な成長を約束しています。ヘルスケアのインフラが改善しつつある新興経済諸国は、吸入・点鼻スプレーのジェネリック医薬品メーカーに有利な機会を提供しています。

主な市場の統計
基準年[2023] 80億9,000万米ドル
予測年[2024] 87億8,000万米ドル
予測年 [2030] 144億3,000万米ドル
CAGR(%) 8.61%

適応症アレルギー性鼻炎に対する迅速かつ即時的な症状緩和のためのジェネリック医薬品へのニーズ

アレルギー性鼻炎は、IgEを介した炎症を誘発するアレルゲンの暴露によって引き起こされる炎症性疾患で、くしゃみ、かゆみ、鼻づまり、鼻漏などの症状を伴う。これらの症状を管理し緩和するために、コルチコステロイドや抗ヒスタミン剤を含む点鼻薬のジェネリック医薬品が広く使用されています。慢性炎症性疾患である喘息は、気流閉塞と気管支痙攣を引き起こします。気管支拡張薬や吸入コルチコステロイドなどのジェネリック医薬品の吸入は、この症状の管理に不可欠です。慢性閉塞性肺疾患は、息切れの増加を特徴とする進行性の肺疾患群です。気管支拡張薬、吸入コルチコステロイド、ホスホジエステラーゼ-4阻害薬などのジェネリック医薬品は、COPDの管理に吸入で使用されます。

年齢層:2~5歳児向けの製品開発が増加中

吸入薬や点鼻薬のジェネリック医薬品を使用する成人のユーザーは、一般的に喘息、慢性閉塞性肺疾患(COPD)、アレルギー性鼻炎の治療を求めています。この層にとって、薬の有効性、使用の利便性、費用対効果はニーズに基づく嗜好です。小児集団、特に2~5歳の小児集団は、安全性が高く、投与量が少なく、年齢層に合わせて特別に調整された吸入・点鼻スプレーを必要としています。小児用製剤は多くの場合、より嗜好性が高く、年齢に適した送達機構を備えています。年少の小児グループと同様に、6~12歳の小児にも、安全で、小児に特化した用量の吸入・点鼻薬が必要です。しかし、この年齢層の小児は、定量吸入器(MDI)のような特定のタイプの吸入器を自分で管理する能力が高まっています。

流通チャネル:競合価格と利便性を提供するオンライン薬局の人気の高まり

吸入薬や点鼻薬のジェネリック医薬品を入手する上で、病院内のメディカルストアは重要な拠点であり、入院患者には即時性を、退院患者や予約のために訪れる患者には利便性を提供しています。これらの店舗は主に、緊急治療や急性期治療のニーズに対応しており、薬の即時投与が不可欠です。オンライン薬局は、ジェネリック医薬品の流通チャネルとして成長しており、利便性としばしば競合価格を提供しています。オンライン薬局は、特に汚名を着せられる可能性のある疾患や、定期的な長期投薬が必要な慢性疾患の管理など、慎重さを重視するハイテクに精通した消費者に対応しています。小売薬局は、吸入薬や点鼻薬のジェネリック医薬品を必要とする患者にとって、最も一般的で利用しやすい店舗です。小売薬局は急性および慢性の治療ニーズに対応しており、特にオンライン配送のスケジュールや病院の場所が不便な場合に、すぐにアクセスできる場所として好まれています。

地域別インサイト

南北アメリカの吸入・点鼻スプレージェネリック医薬品市場は、慢性閉塞性肺疾患(COPD)や喘息を含む呼吸器疾患の有病率の高さ、有利な償還政策、整備されたヘルスケアインフラを背景に、採用が拡大しています。ジェネリック医薬品の参入は、ブロックバスター吸入薬の特許切れに支えられ、メーカー間の競争が激化しているため、医薬品の価格がより手頃になっています。米国肺協会をはじめとする団体による取り組みも、呼吸器疾患に対する認識を高めるのに役立っており、吸入・点鼻スプレーの需要をさらに押し上げています。EMEA地域は、経済、規制、ヘルスケア環境の違いにより、多様な市場力学を示しています。欧州市場は比較的成熟しており、高品質のヘルスケアを重視し、厳しい規制が存在するため、ジェネリック吸入・点鼻スプレー市場の着実な成長に寄与しています。中東とアフリカは、大きな成長の可能性を秘めた新興市場です。欧州におけるジェネリック医薬品採用の増加は、ヘルスケア費用が増加する中、コスト抑制策が後押ししています。中東・アフリカでは、ヘルスケアインフラの改善と医薬品へのアクセスの向上が市場成長の原動力となっています。アジア太平洋地域は、ジェネリック産業の拡大、医療費の増加に後押しされ、吸入・点鼻スプレージェネリック医薬品市場において最も高い成長率を示すと予想されます。ジェネリック医薬品を促進する政府の取り組みや、製薬会社による生産施設の設立も、APACにおける吸入・点鼻スプレージェネリック医薬品市場の将来にとってポジティブな指標です。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、吸入・点鼻スプレーのジェネリック医薬品市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、吸入・点鼻スプレーのジェネリック医薬品市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1.吸入・点鼻スプレーのジェネリック医薬品市場の市場規模および予測は?

2.吸入・点鼻スプレーのジェネリック医薬品市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3.吸入・点鼻スプレーのジェネリック医薬品市場の技術動向と規制枠組みは?

4.吸入・点鼻スプレーのジェネリック医薬品市場における主要ベンダーの市場シェアは?

5.吸入・点鼻スプレーのジェネリック医薬品市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • ジェネリック医薬品の低コスト
      • 呼吸器疾患の罹患率の増加
      • 小児用ネブライザーの大幅な導入
    • 抑制要因
      • ジェネリック医薬品に対する厳しい規制
    • 機会
      • ブロックバスター医薬品の特許切れとFDA承認の増加
      • 製薬会社の研究開発投資の増加
    • 課題
      • 複数のプレーヤーが存在するため価格圧力が高まっている
  • 市場セグメンテーション分析
    • 適応症:アレルギー性鼻炎のジェネリック医薬品による迅速かつ即時の症状緩和の必要性
    • 年齢層:2~5歳の子供向けの製品開発を強化
    • 流通チャネル:競争力のある価格と利便性を提供するオンライン薬局の人気が高まっている
  • 市場動向分析
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制枠組みの分析
  • 顧客のカスタマイズ
    • 処方と投与装置の変更

第6章 吸入・点鼻スプレーのジェネリック医薬品市場適応症別

  • アレルギー性鼻炎
  • 喘息
  • 慢性閉塞性肺疾患

第7章 吸入・点鼻スプレーのジェネリック医薬品市場:年齢層別

  • 大人
  • 2歳から5歳までの子供
  • 6歳から12歳までの子供

第8章 吸入・点鼻スプレーのジェネリック医薬品市場:クラス別

  • アレルギーブロッカー
  • 抗コリン剤
  • 抗ヒスタミン薬
  • 充血除去薬
  • 肥満細胞抑制剤
  • 鼻用ステロイド

第9章 吸入・点鼻スプレーのジェネリック医薬品市場:ルート別

  • 吸入
  • 鼻スプレー
  • トロピカルローション

第10章 吸入・点鼻スプレーのジェネリック医薬品市場:流通チャネル別

  • 病院医療用品店
  • オンライン薬局
  • 薬局小売業

第11章 南北アメリカの吸入・点鼻スプレーのジェネリック医薬品市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の吸入・点鼻スプレーのジェネリック医薬品市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの吸入・点鼻スプレーのジェネリック医薬品市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス、2023
  • 競合シナリオ分析
    • ユージアファーマ、ブデソニドジェネリックの米国FDA承認を取得
    • アンファスター・ファーマシューティカルズ、ナロキソン塩酸塩点鼻薬4mgのFDA承認を取得
    • アムニール、ナロキソン塩酸塩点鼻薬(USP、4mg)の簡略新薬申請が米国FDAに受理されたと発表

第15章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRI
目次
Product Code: MRR-032A67D9141A

[190 Pages Report] The Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 8.09 billion in 2023 and expected to reach USD 8.78 billion in 2024, at a CAGR 8.61% to reach USD 14.43 billion by 2030.

Inhalation and nasal sprays generic drugs are off-patent pharmaceuticals that are bioequivalent to their branded counterparts. They contain the same active ingredients, are administered through the same route of administration, and are intended to have the same therapeutic effect as the original medications. These generic medications are often produced following the original drug's exclusive patent period and are typically offered at a lower cost, enabling wider accessibility to patients requiring treatment for respiratory conditions, allergies, and other nasal or pulmonary issues. The market for inhalation and nasal spray generic drugs is primarily driven by the increasing prevalence of respiratory diseases, the cost-effectiveness of generic products, and patent expiries of branded drugs. Enhanced accessibility in emerging markets and growing acceptance of self-medication for minor ailments also contribute to market growth. However, stringent regulatory frameworks that necessitate extensive documentation and clinical trials potentially delay product commercialization. Competition from branded drugs, limited healthcare budgets, and pricing pressures also pose significant hurdles for inhalation and nasal spray generic businesses. Despite the challenges, research and development in bioequivalent generic drugs with better delivery systems and patient compliance aspects promise potential growth. Developing economies with improving healthcare infrastructure present lucrative opportunities for generic inhalation and nasal spray generic drug manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 8.09 billion
Estimated Year [2024] USD 8.78 billion
Forecast Year [2030] USD 14.43 billion
CAGR (%) 8.61%

Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis

Allergic rhinitis is an inflammatory condition caused by allergen exposure that triggers IgE-mediated inflammation, with symptoms such as sneezing, itching, nasal congestion, and rhinorrhea. Generic drugs in the form of nasal sprays, including corticosteroids and antihistamines, are widely used to manage and relieve these symptoms. Asthma, a chronic inflammatory disease, leads to airflow obstruction and bronchospasm. Inhalation of generic drugs, including bronchodilators and inhaled corticosteroids, are essential in the management of this condition. Chronic obstructive pulmonary disease is a group of progressive lung diseases characterized by increasing breathlessness. Generic medications, including bronchodilators, inhaled corticosteroids, and phosphodiesterase-4 inhibitors, are used inhaled to manage COPD.

Age Group: Increasing product development for children aged 2 to 5

Adult users of inhalation and nasal spray generic drugs commonly seek treatment for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. For this demographic, medication effectiveness, convenience of use, and cost-effectiveness are need-based preferences. The pediatric population, particularly those aged 2 to 5, require inhalation and nasal sprays that are safe, have a lower dosage, and are tailored specifically for their age group. Pediatric formulations are often designed to be more palatable and come with age-appropriate delivery mechanisms. Similar to the younger pediatric group, children aged 6 to 12 require inhalation and nasal sprays that are safe and specifically dosed for them. However, the capacity for children in this age bracket to manage certain inhaler types themselves, such as metered-dose inhalers (MDIs), increases.

Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience

Hospital medical stores are critical points of access for inhalation and nasal spray generic drugs, providing immediacy to in-patients and convenience to those being discharged or visiting for appointments. These stores primarily cater to the need for emergency care and acute treatments where the immediate administration of the medication is imperative. Online pharmacies represent a growing distribution channel for generic drugs, offering convenience and often competitive pricing. They cater to tech-savvy consumers who value discretion, particularly for conditions that may carry a stigma or for managing chronic conditions that require regular, long-term medication regimens. Retail pharmacies are the most common and accessible outlets for patients requiring inhalation and nasal spray generic drugs. They cater to both acute and chronic treatment needs and are a preferred choice for immediate access, especially when online delivery timelines or hospital locations are not convenient.

Regional Insights

The market for inhalation and nasal spray generic drugs in the Americas has been demonstrating growing adoption, with a high prevalence of respiratory disorders, including chronic obstructive pulmonary disease (COPD) and asthma, favorable reimbursement policies, and a well-established healthcare infrastructure. The entry of generic drugs has been supported by patent expirations of blockbuster inhalation drugs, intensifying competition among manufacturers and thus making medications more affordable. Initiatives by organizations, including the American Lung Association, also aid in increasing awareness about respiratory conditions, further driving the demand for inhalation and nasal sprays. The EMEA region exhibits diverse market dynamics owing to varying economic, regulatory, and healthcare environments. The European market is relatively mature, with a strong emphasis on high-quality healthcare and the presence of stringent regulations, contributing to a steady growth in the generic inhalation and nasal spray market. The Middle East and Africa present a nascent market with potential for significant growth. The rise in generic drug adoption in Europe is propelled by cost-containment measures amidst increasing healthcare costs. In the Middle East and Africa, improvements in healthcare infrastructure and increasing access to medicines are catalyzing market growth. The Asia-Pacific is anticipated to exhibit the highest growth rate in the inhalation and nasal spray generic drugs market, bolstered by an expanding generic industry, growing healthcare expenditure. Government initiatives to promote generic medications and the establishment of production facilities by pharmaceutical companies are also positive indicators for the future of the inhalation and nasal spray generic drugs market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Inhalation & Nasal Sprays Generic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Inhalation & Nasal Sprays Generic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Inhalation & Nasal Sprays Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Acerus Pharmaceuticals Corporation, Akorn, Inc., Altaire Pharmaceuticals Inc., Amphastar Pharmaceuticals, Inc., Apotex Inc., AptarGroup, Inc., AstraZeneca PLC, Beximco Pharmaceuticals Ltd., Catalent, Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Mylan N.V., Nephron Pharmaceuticals Corporation, Nippon Shinyaku Co., Ltd., Padagis US LLC, Perrigo Company PLC, Preferred Pharmaceuticals, Inc., Recipharm AB, Sandoz International GmbH, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zhejiang Xianju Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Inhalation & Nasal Sprays Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Allergic Rhinitis
    • Asthma
    • COPD
  • Age Group
    • Adults
    • Children 2 to 5
    • Children 6 to 12
  • Class
    • Allergy Blocker
    • Anticholinergic
    • Antihistamine
    • Decongestant
    • Mast Cell Inhibitor
    • Nasal Steroid
  • Route
    • Inhalation
    • Nasal Spray
    • Tropical Lotion
  • Distribution Channel
    • Hospital Medical Store
    • Online Pharmacy
    • Pharmacy Retail
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Inhalation & Nasal Sprays Generic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Inhalation & Nasal Sprays Generic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Inhalation & Nasal Sprays Generic Drugs Market?

4. What is the market share of the leading vendors in the Inhalation & Nasal Sprays Generic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Inhalation & Nasal Sprays Generic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Low Cost Involved with Generic Prescription Drugs
      • 5.1.1.2. Increasing Prevalence of Respiratory Diseases
      • 5.1.1.3. Significant Adoption of Nebulizers for Children
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent Regulations For Generic Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
      • 5.1.3.2. Growing Investments from Pharmaceutical Companies for R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Pricing Pressure due to Presence of Multiple Players in the Segment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis
    • 5.2.2. Age Group: Increasing product development for children aged 2 to 5
    • 5.2.3. Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization
    • 5.9.1. Changing Formulation & Delivery Device

6. Inhalation & Nasal Sprays Generic Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Allergic Rhinitis
  • 6.3. Asthma
  • 6.4. COPD

7. Inhalation & Nasal Sprays Generic Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Children 2 to 5
  • 7.4. Children 6 to 12

8. Inhalation & Nasal Sprays Generic Drugs Market, by Class

  • 8.1. Introduction
  • 8.2. Allergy Blocker
  • 8.3. Anticholinergic
  • 8.4. Antihistamine
  • 8.5. Decongestant
  • 8.6. Mast Cell Inhibitor
  • 8.7. Nasal Steroid

9. Inhalation & Nasal Sprays Generic Drugs Market, by Route

  • 9.1. Introduction
  • 9.2. Inhalation
  • 9.3. Nasal Spray
  • 9.4. Tropical Lotion

10. Inhalation & Nasal Sprays Generic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Medical Store
  • 10.3. Online Pharmacy
  • 10.4. Pharmacy Retail

11. Americas Inhalation & Nasal Sprays Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Eugia Pharma Gets USFDA Nod for Budesonide Generic
    • 14.3.2. Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
    • 14.3.3. Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio